恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

已收盘 04-30 16:08:13

65.000

-1.550

-2.33%

最高66.500	最低64.700	成交量172.52万
今开66.500	昨收66.550	日振幅2.70%
总市值4,314亿	流通市值167.70亿	总股本66.37亿
成交额1.13亿	换手率0.67%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":65,"timestamp":1777536493003,"preClose":66.55,"halted":0,"volume":1725208,"delay":0,"changeRate":-0.023290758827948867,"floatShares":258000000,"shares":6637000000,"eps":1.18,"marketStatus":"已收盘","change":-1.55,"latestTime":"04-30 16:08:13","open":66.5,"high":66.5,"low":64.7,"amount":112669512,"amplitude":0.027047,"askPrice":65,"askSize":9400,"bidPrice":64.95,"bidSize":3600,"shortable":3,"etf":0,"ttmEps":1.385,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":5,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":66.55,"dividendRate":0.003523,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":0.559871,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":53.88,"timestamp":1777532400000,"preClose":54.99,"halted":0,"volume":71248400,"delay":0,"premium":"+5.22"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2631858446","title":"智通AH统计|4月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=2631858446","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631858446?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:15","pubTimestamp":1777536906,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止4月30日收盘，东北电气、浙江世宝、中石化油服分列AH溢价率前三位，溢价率分别为566.67%、349.34%、297.56%；兆易创新、宁德时代、药明康德分列AH溢价率末三位，溢价率分别为-19.44%、-12.70%、-3.51%。其中安德利果汁、南华期货股份、广汽集团的偏离值位居前三，分别为29.55%、29.35%、25.29%；另外，绿色动力环保、龙蟠科技、大族数控的偏离值位居后三，分别为-21.51%、-20.11%、-19.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["82333","00638","00187","00981","00317","GWLLY","EWH","02333","03145","HK0000306685.HKD","02318","00042","02338","01057","00300","02628","03678","601318","PAImain","HPAD.SI","02208","00568","01989","01349","03750","00470","159982","02465","03200","LU0348766576.USD","03986","82318","01033","LU1244550494.USD","00916","01276","02218","01108","02701","01330","03968","399300","02691","PNGAY","02238","02359","03143","601633","00553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630665375","title":"智通AH统计|4月28日","url":"https://stock-news.laohu8.com/highlight/detail?id=2630665375","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630665375?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:15","pubTimestamp":1777364106,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止4月28日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为558.54%、427.64%、301.85%；兆易创新、宁德时代、药明康德分列AH溢价率末三位，溢价率分别为-17.27%、-15.66%、-7.45%。其中浙江世宝、晨鸣纸业、龙源电力的偏离值位居前三，分别为96.06%、26.75%、26.70%；另外，绿色动力环保、广合科技、金风科技的偏离值位居后三，分别为-19.54%、-18.15%、-17.49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00300","03678","EWH","02691","06031","01033","00553","00470","159982","00317","03986","LU0164865239.USD","03968","LU0072913022.USD","01330","03143","02603","LU1988902786.USD","01057","BK1135","02009","03996","02218","02701","LU0117841782.USD","01812","02338","00042","00568","01989","09981","02208","00916","01349","00588","02899","09611","03750","BK1193","01108","01276","LU0266512127.USD","LU2097828631.EUR","03908","LU0320764599.SGD","02465","IE00B0169L03.USD","02359","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630602365","title":"智通AH统计|4月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=2630602365","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630602365?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:15","pubTimestamp":1777277705,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止4月27日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为542.86%、362.20%、301.49%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-21.47%、-19.59%、-6.32%。其中龙源电力、浙江世宝、南华期货股份的偏离值位居前三，分别为33.96%、31.22%、24.81%；另外，剑桥科技、金风科技、广和通的偏离值位居后三，分别为-31.05%、-24.84%、-18.55%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01033","00386","02208","03968","02338","03200","06166","03750","00638","03328","LU0307460666.USD","BK1231","03143","00568","02691","09981","LU2045819591.USD","06680","BK1105","00300","IE00B3M56506.USD","06031","02701","BK1594","03969","02218","03678","00042","02899","01276","03996","00588","LU0287142896.SGD","01108","LU1328277881.USD","02359","LU1051768304.USD","00553","01057","00916","03986","00470","LU1880383440.USD","02603","IE00BVYPNP33.GBP","LU0149721374.USD","00187","01330","01349"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630368994","title":"交银国际：升恒瑞医药(01276)目标价至74港元 首季业绩延续高增长态势","url":"https://stock-news.laohu8.com/highlight/detail?id=2630368994","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630368994?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:06","pubTimestamp":1777273611,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，恒瑞医药首季业绩延续去年的高增长态势，创新药尤其是非肿瘤产品快速放量，在整体产品销售中的比例超过60%，创新转型已基本成功。基于首季业绩表现，交银国际上调恒瑞医药2026至2028年利润率预测，上调净利润预测3%至4%，并认为公司当前估值合理，上调目标价至74港元，维持“中性”评级。报告指，恒瑞医药首季收入/扣非净利润分别增长13%/17%，整体业绩略超该行此前的预期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600276","EWH","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630847355","title":"创新成果持续落地、国际化再迎里程碑，挖掘恒瑞医药(01276)一季报背后的投资确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2630847355","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630847355?lang=zh_cn&edition=full","pubTime":"2026-04-27 10:28","pubTimestamp":1777256930,"startTime":"0","endTime":"0","summary":"4月22日晚，恒瑞医药正式发布了2026年第一季度经营业绩。而在临床研发方面，恒瑞医药今年一季度累计取得临床试验批准通知26个;2026年以来获得CDE突破性治疗品种认定6项。报告期内，公司创新药对外许可业务确认收入7.87亿元，主要系GSK确认的收入。近期，恒瑞医药国际化发展迎来新的里程碑。此前，Kailera公司已向恒瑞医药支付了1亿美元不可退还首付款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434202.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","LU1781817850.SGD","LU2580892862.HKD","LU2543165471.USD","600276","LU1655091616.SGD","BK0183","LU0405327494.USD","LU2097828631.EUR","LU2289578879.USD","LU1580142542.USD","LU0359201612.USD","LU2097828557.USD","LU1328615791.USD","LU2580892789.USD","LU1255011170.USD","LU2488822045.USD","LU1146622755.USD","LU2097828805.USD","LU1997244956.HKD","LU1969619763.USD","BK0060","LU0405327148.USD","BK0196","BK0028","LU1997245177.USD","LU0359201885.HKD","LU2097828714.EUR","LU2148510915.USD","BK1191","LU2328871848.SGD","LU1064131003.USD","BK0012","BK0239","LU1820825898.SGD","LU2495084118.USD","LU0359202008.SGD","LU1997245094.SGD","LU2097828474.EUR","BK0188","LU1023057109.AUD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630879944","title":"花旗：恒瑞医药给予“买入”评级 目标价134港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630879944","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630879944?lang=zh_cn&edition=full","pubTime":"2026-04-25 10:15","pubTimestamp":1777083300,"startTime":"0","endTime":"0","summary":"　　花旗发布研报称，给予恒瑞医药H股目标价134港元以及“买入”评级。花旗指出，恒瑞医药2026年第一季创新药销售年增26%至45亿元人民币，占产品销售比重由去年同期的54%提升至62%。　　公司管理层重申2026年创新药销售年增超过30%的目标，并指出3月医院准入加速，为全年销售增长奠定基础。公司2026年第一季确认来自葛兰素史克合作的BD收入7.87亿元人民币，全年预计约2.5亿元人民币。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-04-25/doc-inhvsqpe7283823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600276","EWH","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629950788","title":"瑞银：升恒瑞医药(01276)目标价至97.4港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2629950788","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629950788?lang=zh_cn&edition=full","pubTime":"2026-04-24 10:54","pubTimestamp":1776999295,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，基于2026年第一季业绩，由于研发进展，上调恒瑞医药(01276)长期销售预测。目标价由91港元升至97.4港元，维持“买入”评级。恒瑞医药首季营收同比增13%至81.4亿元人民币，略低于市场预测85.3亿元人民币及该行预测88.1亿元人民币;净利润增长21.8%至22.8亿元人民币，大致符合市场预测21.8亿元人民币及该行预测23.3亿元人民币。第一季毛利率同比增1.4个百分点至86.6%; 净利润率上升2个百分点至28%。第一季研发投资达22.2亿人民币，其中16.5亿元人民币计入费用;销售费用率下降0.3个百分点至27%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629864397","title":"T3出行、明珠化工、圆心科技递表港交所主板；平安好医生、中国电信、恒瑞医药发布一季度报告丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2629864397","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629864397?lang=zh_cn&edition=full","pubTime":"2026-04-24 07:00","pubTimestamp":1776985211,"startTime":"0","endTime":"0","summary":"｜2026年4月24日星期五｜NO.1T3出行、明珠化工、圆心科技递表港交所主板据港交所4月22日消息，南京领行科技股份有限公司（以下简称T3出行）、湖南明珠矿用化工科技股份有限公司（以下简称明珠化工）、北京圆心科技集团股份有限公司（以下简称圆心科技）已向港交所主板提交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604243716838768.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243716838768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1580142542.USD","HK0000352382.USD","01276","01833","LU1328615791.USD","LU1997245094.SGD","BK1191","LU1655091616.SGD","LU2580892862.HKD","BK1142","BK0028","BK1617","LU2328871848.SGD","LU1064130708.USD","HK0000352291.HKD","HK0000288784.HKD","600276","BK0060","LU2097828631.EUR","LU0405327494.USD","LU2289578879.USD","LU2097828805.USD","00728","LU2148510915.USD","BK0239","IPOS","LU2495084118.USD","LU2580892789.USD","LU0039217434.USD","LU1146622755.USD","BK1219","BK1506","BK1610","LU2488822045.USD","LU1255011170.USD","LU2097828557.USD","LU1997245177.USD","601728","LU2097828474.EUR","BK0261","BK1247","LU2543165471.USD","BK1589","LU0359201885.HKD","SGXZ49509284.SGD","BK1615","BK1536","LU1781817850.SGD","LU1969619763.USD","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629836502","title":"恒瑞医药：二级市场波动受多重因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2629836502","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629836502?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:19","pubTimestamp":1776943140,"startTime":"0","endTime":"0","summary":"证券日报网讯4月23日，恒瑞医药在互动平台回答投资者提问时表示，二级市场波动受多重因素影响。公司目前经营稳定，严守合规底线，高标准、严要求、全方位打造合规文化，不断巩固合规意识，确保全面高质量合规，推动公司业务可持续发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233716339814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245177.USD","BK0239","LU2097828714.EUR","LU2580892862.HKD","LU2097828631.EUR","LU2543165471.USD","LU1064130708.USD","LU1655091616.SGD","LU2148510915.USD","LU2097828805.USD","LU2488822045.USD","LU1146622755.USD","LU1328615791.USD","LU2328871848.SGD","LU1580142542.USD","LU1064131003.USD","600276","BK0196","LU2495084118.USD","LU1997244956.HKD","LU1255011170.USD","BK0028","LU1781817850.SGD","LU1820825898.SGD","LU2097828474.EUR","BK0012","LU1969619763.USD","LU0359201612.USD","LU0405327148.USD","LU2580892789.USD","BK0188","BK1191","BK0183","LU0405327494.USD","LU0359202008.SGD","01276","LU2097828557.USD","BK0060","LU1997245094.SGD","LU1023057109.AUD","LU2289578879.USD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629854198","title":"智通AH统计|4月23日","url":"https://stock-news.laohu8.com/highlight/detail?id=2629854198","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629854198?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:15","pubTimestamp":1776932108,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止4月23日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为558.54%、345.30%、303.33%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-25.17%、-19.16%、-6.60%。其中华勤技术、龙源电力、东北电气的偏离值位居前三，分别为41.36%、27.55%、25.00%；另外，剑桥科技、长城汽车、中金公司的偏离值位居后三，分别为-35.74%、-21.79%、-19.68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02899","00317","01276","01033","LU0456827905.SGD","EWH","GWLLY","159982","00956","03296","02009","LU0348767384.USD","LU0061477393.USD","02208","82333","601633","00470","03968","00895","03328","01349","399300","09611","02218","00042","02338","LU0231483743.USD","02603","06031","03986","01108","IE00B031J352.USD","03143","00300","06166","03678","00553","03969","02701","BK1516","00916","01812","03750","00187","02359","01057","03908","06613","02333"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629607068","title":"港股异动 | 恒瑞医药(01276)绩后涨超5% 一季度归母净利同比增加21.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629607068","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629607068?lang=zh_cn&edition=full","pubTime":"2026-04-23 09:36","pubTimestamp":1776908175,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药绩后涨超5%，截至发稿，涨3.22%，报68.85港元，成交额1.35亿港元。消息面上，4月22日，恒瑞医药发布公告，于2026年第一季度，该集团取得营业收入人民币81.41亿元，同比增加12.98%；归属于上市公司股东的净利润22.82亿元，同比增加21.78%；基本每股收益0.34元。2026年第一季度，公司创新药销售收入45.26亿元，同比增长 25.75%，占药品销售收入的比重达61.69%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","LU1328615791.USD","BK0012","BK4588","LU0405327148.USD","LU2495084118.USD","LU1997245177.USD","LU0359202008.SGD","LU2580892789.USD","LU1655091616.SGD","LU0359201885.HKD","LU1255011170.USD","LU2488822045.USD","BK1191","BK4585","LU1580142542.USD","LU2148510915.USD","BK0188","600276","LU1820825898.SGD","BK0196","LU1064131003.USD","BK0028","LU2580892862.HKD","LU1781817850.SGD","LU0359201612.USD","LU1023057109.AUD","LU2328871848.SGD","LU2097828714.EUR","LU2097828557.USD","LU1064130708.USD","LU1997244956.HKD","LU2097828474.EUR","LU2543165471.USD","BK0239","BK0183","LU1146622755.USD","LU1969619763.USD","LU1997245094.SGD","LU2289578879.USD","LU2097828631.EUR","LU2097828805.USD","01276","VXUS","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100109576","title":"异动解读 | 一季度业绩亮眼，创新药收入大增，恒瑞医药盘中大涨5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100109576","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100109576?lang=zh_cn&edition=full","pubTime":"2026-04-23 09:35","pubTimestamp":1776908115,"startTime":"0","endTime":"0","summary":"恒瑞医药今日盘中股价大幅拉升，涨幅一度达到5.31%，表现强势。报告显示，公司第一季度实现营业收入81.41亿元，同比增长12.98%；归属于上市公司股东的净利润为22.82亿元，同比大幅增长21.78%。尤为亮眼的是，创新药销售收入达到45.26亿元，同比增长25.75%，占药品销售收入的比重提升至61.69%，收入结构持续优化。第一季度，公司创新药对外许可业务确认收入7.87亿元，成为新的增长引擎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629608077","title":"港股公告掘金 | 恒瑞医药一季度归母净利润同比增加21.78% 赛力斯拟回购最多20亿元A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629608077","media":"智通财经","labels":["shareholding","dataReport","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629608077?lang=zh_cn&edition=full","pubTime":"2026-04-23 09:03","pubTimestamp":1776906229,"startTime":"0","endTime":"0","summary":"【重大事项】华勤技术(03296)：香港公开发售获531.33倍认购 每股发售价77.7港元赛力斯(09927)拟回购10亿-20亿元的A股 助力价值回归博泰车联(02889)与地平线签署战略合作协议 共同打造汽车智能化、国产化的平台级解决方案康耐特光学(02276)与一家在智能眼镜领域占据行业领导地位的全球领先科技企业签署合作备忘录达力普控股(01921)附属拟引入库卡AI智能机器人技术 积极推","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997244956.HKD","LU2580892789.USD","LU0359202008.SGD","601127","BK1588","IE0034224299.USD","LU2517655291.USD","600276","LU1655091616.SGD","LU0531971595.HKD","LU2488822045.USD","SG9999001093.SGD","LU2097828474.EUR","LU1969619763.USD","LU0405327148.USD","LU1997245177.USD","LU1820825898.SGD","LU1328615791.USD","LU2543165471.USD","BK0028","LU1064130708.USD","LU0605514214.HKD","BK4588","BK1228","LU0650527681.SGD","SG9999002950.SGD","LU2097828805.USD","BK0183","LU2148510915.USD","LU2517655374.HKD","BK0239","LU0039217434.USD","BK0060","SG9999006597.SGD","LU2517655028.SGD","LU1064131003.USD","LU2580892862.HKD","BK4585","BK0264","LU0594300419.USD","LU2328871848.SGD","LU2495084118.USD","BK1109","BK1119","LU2289578879.USD","BK1095","BK0201","BK0012","LU1580142542.USD","BK0185","LU1880383440.USD","SG9999001051.SGD","BK1191","LU2097828557.USD","LU2097828631.EUR","LU0307460666.USD","BK1519","BK0014","LU0588546209.SGD","LU0871576103.HKD","BK0188","BK0196","LU1255011170.USD","LU0405327494.USD","01276","LU0359201612.USD","LU0359201885.HKD","SG9999001069.SGD","09927","LU1023057109.AUD","LU0594300179.USD","BK1193","LU2097828714.EUR","LU0164865239.USD","LU1880383366.USD","LU1146622755.USD","BK1596","BK1556","LU1997245094.SGD","LU1781817850.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629071540","title":"智通港股早知道 | 中办、国办：持续推进绿色交通基础设施建设 恒瑞医药(01276)一季度归母净利润同比增加21.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629071540","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629071540?lang=zh_cn&edition=full","pubTime":"2026-04-23 07:22","pubTimestamp":1776900146,"startTime":"0","endTime":"0","summary":"恒瑞医药发布第一季度业绩，归母净利润22.82亿元 同比增加21.78%恒瑞医药发布公告，于2026年第一季度，该集团取得营业收入人民币81.41亿元，同比增加12.98%；归属于上市公司股东的净利润22.82亿元，同比增加21.78%；基本每股收益0.34元。经营利润同比上升44.8%至1.803亿美元。截至2026年2月28日止首九个月，净营收为41.318亿美元，同比增加13.0%。经营利润为5.575亿美元，同比增加27.6%。新东方股东应占净利润为4.13亿美元，同比增加13.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432376.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","VXUS","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629127880","title":"创新药收入占比首破六成，恒瑞医药Q1营收81亿元，净利同增22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629127880","media":"华尔街见闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629127880?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:22","pubTimestamp":1776853336,"startTime":"0","endTime":"0","summary":"恒瑞医药一季报显示，公司实现营收81.41亿元，同比增长12.98%；归母净利润22.82亿元，同比增长21.78%。创新药销售收入占比首次突破六成，达61.69%，其中非肿瘤产品收入同比增长92.13%，多元化趋势明显。报告期内累计研发投入22.24亿元，3项创新成果获批，8项新药上市申请获受理，管线推进节奏加快。","market":"nz","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3770612","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"创新药收入占比首破六成，恒瑞医药Q1营收81亿元，净利同增22%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600276","159992","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180885491","title":"恒瑞医药2026年第一季度营收81.41亿元，经调整净利润22.82亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180885491","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180885491?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:56","pubTimestamp":1776851767,"startTime":"0","endTime":"0","summary":"恒瑞医药2026年第一季度实现营收81.41亿元，同比增长12.98%。经调整净利润22.82亿元，同比提升21.78%。毛利率约为86.58%，经营利润率约为32.04%。经营活动现金流达7.86亿元，同比增加41.66%。销售及管理费用合计约28.14亿元，占营收比重约34.58%。同期，研发投入保持在较高水平，费用化研发为16.51亿元，同比上升约7.70%，体现了持续发力创新的战略导向。其中，抗肿瘤创新药收入33.13亿元，同比增长11.63%；非肿瘤创新药收入12.13亿元，同比增长92.13%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药2026年第一季度营收81.41亿元，经调整净利润22.82亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629019821","title":"恒瑞医药：第一季度净利润22.82亿元，同比增长21.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629019821","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629019821?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:12","pubTimestamp":1776849143,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月22日，恒瑞医药（HK1276）公告，2026年第一季度营业收入81.41亿元，同比增长12.98%。净利润22.82亿元，同比增长21.78%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223714119581.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223714119581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600276","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629086542","title":"智通AH统计|4月21日","url":"https://stock-news.laohu8.com/highlight/detail?id=2629086542","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629086542?lang=zh_cn&edition=full","pubTime":"2026-04-21 16:15","pubTimestamp":1776759306,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止4月21日收盘，东北电气、浙江世宝、中石化油服分列AH溢价率前三位，溢价率分别为592.31%、329.12%、296.34%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-27.15%、-16.81%、-6.99%。其中东北电气、胜宏科技、长飞光纤光缆的偏离值位居前三，分别为69.47%、25.83%、23.66%；另外，金风科技、晨鸣纸业、绿色动力环保的偏离值位居后三，分别为-30.15%、-23.59%、-22.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02338","02359","BYDDY","00187","01330","01349","03750","02691","00042","01057","02603","06031","01211","399300","HK0000252160.HKD","159982","HYDD.SI","01276","03678","00300","00317","06865","02899","LU1244550577.SGD","06869","EWH","02068","02701","06166","03968","01033","00553","00638","02218","002594","00895","03143","LU0128522157.USD","03986","02208","BK1140","LU0672654166.SGD","02476","00525","03908","01812","01108","81211","00916"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628479357","title":"恒瑞医药(01276)：HRS9531注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2628479357","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628479357?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:32","pubTimestamp":1776684735,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS9531注射液的《药物临床试验批准通知书》，将于近期开展临床试验。HRS9531注射液是以HRS9531为主要活性成分，具有全球自主知识产权的新型靶向抑胃肽受体和胰高血糖素样肽-1受体的双激动剂，其用于成人长期体重管理的上市申请已于2025年9月获国家药监局受理。截至目前，HRS9531相关项目累计研发投入约6.32亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","LU1328615791.USD","BK0012","LU0405327148.USD","LU2495084118.USD","LU1997245177.USD","LU0359202008.SGD","LU2580892789.USD","LU1655091616.SGD","LU0359201885.HKD","LU1255011170.USD","LU2488822045.USD","BK1191","LU1580142542.USD","LU2148510915.USD","BK0188","600276","LU1820825898.SGD","LU1064131003.USD","BK0196","BK0028","LU2580892862.HKD","LU1781817850.SGD","LU0359201612.USD","LU1023057109.AUD","LU2328871848.SGD","LU2097828714.EUR","LU2097828557.USD","LU1064130708.USD","LU1997244956.HKD","LU2097828474.EUR","LU2543165471.USD","BK0239","LU1146622755.USD","BK0183","LU1969619763.USD","LU1997245094.SGD","LU2289578879.USD","LU2097828631.EUR","LU2097828805.USD","01276","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628982748","title":"智通AH统计|4月20日","url":"https://stock-news.laohu8.com/highlight/detail?id=2628982748","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628982748?lang=zh_cn&edition=full","pubTime":"2026-04-20 16:15","pubTimestamp":1776672905,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止4月20日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为592.31%、325.57%、296.09%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-26.26%、-17.85%、-6.54%。其中东北电气、长飞光纤光缆、吉宏股份的偏离值位居前三，分别为75.24%、26.93%、23.68%；另外，金风科技、晨鸣纸业、绿色动力环保的偏离值位居后三，分别为-31.49%、-24.69%、-20.83%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02068","159982","002594","02359","LU0708995153.HKD","03908","LU1868838027.USD","01057","01618","02603","00916","03750","BYDDY","01211","06031","02899","01349","00317","03968","81211","00187","00300","03986","02701","LU1328277881.USD","01033","03268","EWH","00553","00638","01108","06865","01989","LU0287142896.SGD","LU0979878070.USD","02208","00895","01276","06613","00042","03678","HYDD.SI","01330","399300","02338","06869","02218","01812","03143"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0172},{"period":"3month","weight":-0.0453},{"period":"6month","weight":-0.1119},{"period":"1year","weight":0.5108},{"period":"ytd","weight":-0.0627}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.055},{"period":"3month","weight":-0.0664},{"period":"6month","weight":0.0079},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}